跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS
Authorized
STANDARD
APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS
Apotex Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f36ea4fb997b01be
Company
Apotex Inc
Type
Standard
Approval Details
Approval Id
f36ea4fb997b01be
Drug Approval Canada Name
APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS
Product Name
APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS
Status
Dormant
Status Date
2025-04-19
Original Market Date
2022-04-26
Din
02467119
Drug Class
Human
Dosage Form
Tablet (Extended-Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:16.04.16
Atc Original
N06AX23 DESVENLAFAXINE
Atc Name
n 06 ax 23
Aig Number
0152509001
Company Name
Apotex Inc
Company Address
150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path
/organization/apotex-inc
Company Information
Pharmaceutical Company Name
Apotex Inc
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
150 Signet Dr
Active Ingredients
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f36ea4fb997b01be
Type
Standard
Back to Health Canada Approvals
